Shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) skyrocketed 100% following the company’s announcement that its diaper rash product is now available at Walmart stores and other leading U.S. retail chains.

The healthcare firm revealed that its antimicrobial hydrogel, built on its patented Microcyn technology using stabilized hypochlorous acid (HOCl), is currently stocked in 3,600 Walmart locations, on Amazon.com, and in several major grocery chains nationwide.

This launch represents Sonoma’s first significant push into the over-the-counter consumer market through large-scale retail distribution, facilitated by the company’s U.S.-based distribution partner.

“We are excited to see our strategy of expanding into the over-the-counter space begin to take hold with our first U.S. product targeted to consumers launched into large scale retail channels,” said Amy Trombly, CEO of Sonoma. “We are also pleased about the increased availability of our Microcyn technology for consumers who seek safe and effective solutions for diaper rash and other skin irritations.”

Sonoma Pharmaceuticals develops a variety of products leveraging its Microcyn technology for applications including wound care, eye, oral and nasal care, dermatology, podiatry, and animal health.

Sonoma Pharmaceuticals stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.